Sprouty RTK signaling antagonist 4 (SPRY4)

Sprouty RTK signaling antagonist 4 (SPRY4) is a cysteine- and proline-rich intracellular protein that acts as a negative regulator of the receptor tyrosine kinase (RTK) and mitogen-activated protein kinase (MAPK) signaling pathways[1][3][6][7]. By inhibiting the formation of active GTP-bound RAS, SPRY4 modulates cell proliferation, apoptosis, and migration, impacting various biological contexts such as organ development, embryogenesis, inflammation, and tissue homeostasis[1]. Dysregulation of SPRY4 function or expression is implicated in numerous cancers, where it may act as either a tumor suppressor or an oncogene, and in developmental disorders such as hypogonadotropic hypogonadism with or without anosmia[1][6][7]. SPRY4's nuanced role in balancing RTK signaling makes it a factor of interest in oncology and developmental biology, though it is not yet a direct target for approved pharmacological intervention.

Other names

Protein sprouty homolog 4SPRY4Spry-4HH17sprouty homolog 4spry4

Negative feedback inhibition of MAPK pathway by blocking formation of active GTP-RAS; Inhibition of downstream ERK signaling; Interference with integrin-mediated cell migration.